Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716138 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 5
- Study locations
NCT06716138: Recruiting Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, sponsored by Avistone Biotechnology Co..
NCT06716138 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 96 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06716138, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Interventions
- DRUG ANS03
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center - New York
Fujian
- Research Site - Fuzhou
Guangdong
- Research Site - Guangzhou
Shanghai Municipality
- Research Site - Shanghai
Sichuan
- Research Site - Chengdu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 1 |
What NCT06716138 shows while recruiting
NCT06716138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration appearing as the primary indexed condition, and to 1 intervention - of which ANS03 is the first listed.
NCT06716138 lists 5 locations in 5 states (New York, Fujian, Guangdong).
Frequently Asked Questions
What is clinical trial NCT06716138 about?
NCT06716138 is a clinical study titled "A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
What is the current status of trial NCT06716138?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2025-03-06. Estimated completion is 2029-03-30.
What conditions does trial NCT06716138 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration.
What interventions are being tested in trial NCT06716138?
The interventions under investigation include: ANS03 (DRUG).
Who is sponsoring clinical trial NCT06716138?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716138 being conducted?
This trial has 5 study locations across New York, Fujian, Guangdong, Shanghai Municipality, Sichuan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06716138's enrollment target sits among peer trials
96 601st of 2000 higher than 1,391 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI